Soleno Therapeutics (SLNO) awards CCO 28,600 RSUs and options

Rhea-AI Filing Summary

Soleno Therapeutics’ Chief Commercial Officer Manning Meredith received new equity awards. On January 21, 2026, Meredith was granted 28,600 shares of Common Stock in the form of restricted stock units at a grant price of $0. These RSUs are scheduled to vest 100% on December 15, 2027, as long as Meredith continues as a service provider under the company’s 2014 Equity Incentive Plan.

On the same date, Meredith was also granted an employee stock option for 32,800 shares of Common Stock with an exercise price of $43.65 per share. One forty‑eighth of these option shares will vest on February 1, 2026, with additional vesting on each monthly anniversary, subject to continued service. After these transactions, Meredith beneficially owned 72,029 shares of Common Stock directly, including RSUs subject to vesting conditions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Manning Meredith

(Last) (First) (Middle)

100 MARINE PARKWAY, SUITE 400

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		A		28,600(1)	A	$0	72,029(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$43.65	01/21/2026		A		32,800		(3)	01/21/2036	Common Stock	32,800	$0	32,800	D

Explanation of Responses:

1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date.

2. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

3. 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

	/s/ Anish Bhatnagar, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Soleno Therapeutics (SLNO) report for Manning Meredith?

Soleno Therapeutics reported that Chief Commercial Officer Manning Meredith received equity awards on January 21, 2026, including restricted stock units in Common Stock and an employee stock option, as disclosed in a Form 4.

How many Soleno Therapeutics (SLNO) RSUs were granted to the CCO and when do they vest?

Manning Meredith was granted 28,600 RSUs, each representing one share of Common Stock. 100% of these RSUs vest on December 15, 2027, provided Meredith continues as a service provider under the 2014 Equity Incentive Plan through that date.

What are the key terms of the stock options granted to the Soleno (SLNO) CCO?

Meredith received an employee stock option covering 32,800 shares of Common Stock with an exercise price of $43.65 per share. 1/48th of the option shares vest on February 1, 2026, with additional 1/48th portions vesting on each one‑month anniversary, subject to continued service.

How many Soleno Therapeutics (SLNO) shares does the CCO beneficially own after these grants?

Following the reported transactions, Manning Meredith beneficially owned 72,029 shares of Common Stock directly, which include shares underlying RSUs subject to applicable vesting schedules and conditions.

Did the Soleno (SLNO) CCO pay anything to receive the RSUs and options reported?

The Form 4 shows that both the 28,600 RSUs and the grant of the 32,800-share stock option were recorded at a transaction price of $0, consistent with equity awards granted as compensation. The option itself has an exercise price of $43.65 per share if exercised in the future.

What conditions apply to the vesting of the Soleno (SLNO) CCO’s new equity awards?

Both the RSUs and stock options require that Manning Meredith continue as a Service Provider under Soleno’s 2014 Equity Incentive Plan. The RSUs vest fully on December 15, 2027, while the option vests in monthly installments starting on February 1, 2026, each vesting date being conditioned on continued service.